Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location | |
|---|---|---|---|---|
LATAM LOWERS LDL-C |
Hypercholesterolaemia | Phase4 | Argentina Brazil |
NCT06501443 |
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa |
Hidradenitis Suppurativa | Phase3 | Argentina Australia United States |
NCT06799000 |
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) |
Relapsing Multiple Sclerosis | Phase3 | Argentina Austria Belgium Brazil Bulgaria Chile China Colombia Croatia Denmark Georgia Guatemala Hong Kong India Ireland Israel Italy Jordan Latvia Lebanon Lithuania Malaysia Mexico Netherlands Poland Saudi Arabia Slovakia Spain Switzerland Taiwan Turkey United Arab Emirates United Kingdom United States View All |
NCT05147220 |
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma |
Asthma | Phase3 | Argentina Austria Colombia Czechia Greece Guatemala Hungary Italy Mexico Panama Portugal Romania South Africa Spain View All |
NCT05562466 |
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy |
Primary IgA Nephropathy | Phase3 | Argentina Australia Belgium Brazil China Colombia Czechia Denmark France Germany Hong Kong Hungary India Israel Italy Japan Korea, Republic of Malaysia Mexico Netherlands Singapore Slovakia Slovenia Sweden Taiwan Thailand Turkey United Kingdom United States Vietnam View All |
NCT04557462 |
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Bulgaria Canada China Czechia France Germany Guatemala Hungary Japan Malaysia Poland Portugal Romania Spain Taiwan Thailand United States View All |
NCT06133972 |
Iptacopan in Patients With ANCA Associated Vasculitis |
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase2 | Argentina Australia Austria Canada China Czechia Denmark France Germany Hungary Spain Turkey United States View All |
NCT06388941 |
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) |
Primary Immune Thrombocytopenia (ITP) | Phase3 | Argentina Australia Austria Belgium Bulgaria China Czechia France Germany Hong Kong Hungary India Italy Japan Malaysia Mexico Norway Romania Singapore Spain Thailand Turkey United Kingdom United States Vietnam View All |
NCT05653349 |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase3 | Argentina Australia China France Germany Hungary Israel Italy Japan Malaysia Romania Singapore Spain Taiwan Thailand United Kingdom United States View All |
NCT05648968 |
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) |
Polymyalgia Rheumatica | Phase3 | Argentina Australia Canada Chile Colombia Czechia Denmark France Germany Hungary Italy Japan Lebanon Spain Switzerland United States View All |
NCT06331312 |